Article

<i>BRCA1</i> secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance

2023-03-21

Abstract excerpt

BRCA1 splice isoforms Δ11 and Δ11q can contribute to PARP inhibitor (PARPi) resistance by splicing-out the mutation-containing exon, producing truncated, partially-functional proteins. However, the clinical impact and underlying drivers of BRCA1 exon skipping remain undetermined. We analyzed nine ovarian and breast cancer patient derived xenografts (PDX) with BRCA1 exon 11 frameshift mutations for exon skipping...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: dfb9de9f-4084-5d43-af56-66bd1d09df7b
DOI: 10.1101/2023.03.20.23287465

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

<i>BRCA1</i> secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceDOI 10.1101/2023.03.20.23287465Read

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceSemantic proximity Read

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and CisplatinSemantic proximity Read

Decoding the <i>BRCA2</i> reversion principles underlying PARP inhibitor resistanceSemantic proximity Read

Somatic mRNA Analysis of BRCA1 Splice Variants Provides a Direct Theranostic Impact on PARP Inhibitors.Semantic proximity Read

Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.Semantic proximity Read

mRNA splicing variants: exploiting modularity to outwit cancer therapy.Semantic proximity Read

Nanopore sequencing of full-length <i>BRCA1</i> mRNA transcripts reveals co-occurrence of known exon skipping eventsSemantic proximity Read

A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant.Semantic proximity Read

Reversion mutations define minimal <i>BRCA1/2</i> requirements for therapy resistanceSemantic proximity Read

Genomic alterations enable <i>BRCA1</i> methylation loss and promoter bypass to drive resistance in high-grade serous ovarian cancerSemantic proximity Read

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in <i>BRCA1/2</i> -mutant metastatic breast cancerSemantic proximity Read

<i>In-Silico</i> Characterization of <i>TP53</i> Splice Mutations in Somatic and Germline TumoursSemantic proximity Read